Sun Pharma gets U.S. FDA nod for Prevacid generic drug

MUMBAI Sun Sep 15, 2013 12:18pm IST

A worker stocks shelves at a temporary CVS store in the Rockaway Beach neighborhood of Queens, New York, November 13, 2012. REUTERS/Brendan McDermid/Files

A worker stocks shelves at a temporary CVS store in the Rockaway Beach neighborhood of Queens, New York, November 13, 2012.

Credit: Reuters/Brendan McDermid/Files

Related Topics

Stocks

   

MUMBAI (Reuters) - Sun Pharmaceutical Industries Ltd (SUN.NS) said its unit has received U.S. Food and Drug Administration's (USFDA) final approval for the generic version of Prevacid.

The approval is for Lansoprazole Delayed-Release Capsules USP, 15 and 30 mg, which are therapeutic equivalents of Takeda Pharmaceutical Co. Ltd's capsules, the company said in a release late on Saturday.

The capsules have annual sales of $430 million in the United Sates, it said.

The capsules are used for short-term treatment for healing and symptom relief of active duodenal ulcer, it said.

(Reporting by Subhadip Sircar; Editing by Robert Birsel)

FILED UNDER:

Reforms Push

REUTERS SHOWCASE

Reuters Exclusive

Reuters Exclusive

India looks to sway Americans with nuclear power insurance plan  Full Article 

To Boost Growth

To Boost Growth

Crank up public spending to revive growth - chief economic adviser.   Full Article 

Bold Steps

Bold Steps

SpiceJet rescue plan marks bold bet on Indian aviation recovery.   Full Article 

New Airline

New Airline

Tata, Singapore Air venture Vistara to take off on Jan 9.  Full Article 

Online Sales

Online Sales

Knock knock. Who's there? Amazon's best-selling holiday author.  Full Article 

26/11 Plotter

26/11 Plotter

Pakistan to challenge bail for Mumbai attack "mastermind".  Full Article 

Chinese Economy

Chinese Economy

China revises up size of 2013 economy, sees no effect on 2014 growth.  Full Article 

Reuters Poll

Reuters Poll

BSE Sensex to hit 32,980 by December 2015  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage